

6/5/4

DIALOG(R) File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

009720593

WPI Acc No: 1994-000443/*199401*

XRAM Acc No: C94-000200

Incorporating therapeutic gene via vector into body cells - in-vivo or in vitro, for subsequent expression and secretion of active protein, partic. for treating degenerative diseases of spine and nerves

Patent Assignee: WEHLING P (WEHL-I)

Inventor: WEHLING P

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
DE 4219626	A1	19931223	DE 4219626	A	19920616	199401 B

Priority Applications (No Type Date): DE 4219626 A 19920616

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
DE 4219626	A1	9		C12N-015/79	

Abstract (Basic): DE 4219626 A

Method comprises incorporation of a therapeutic gene, by means of vectors, into body cells with subsequent expression, by the genetically modified cells, of therapeutic protein (I) and secretion of (I) into the extracellular environment.

Pref. cells are nerve cells, immune competent cells, mesenchymal and ectodermal cells, esp. peripheral nerve cells, macrophages, lymphocytes, fibroblasts and chondrocytes. Pref. (I) have antiinflammatory, analgesic, regenerative, immunostimulating, hypotensive, anti-degenerative or antiarthrotic activities.

The vector is pref. a retro-, adeno-, adeno-associated or herpes-virus, or a liposome, and may be injected directly, in vivo. Alternatively cells are removed, those cells capable of division selected and the gene introduced in vitro. The modified cells are returned to the donor. In this case the transfected cells may be indentified by co-transfection with a marker. Pref. IL-1 antagonists are IL-1 receptor antagonist and IL-1 receptor.

USE/ADVANTAGE - The method is esp. used to express cytokines (or their inhibitors); opiates; prostaglandins (sic) and their inhibitors; esp. inhibitors of interleukin-1. Esp. is is used to treat degenerative diseases of the spinal column and nerves. Gene transfer should eliminate the need for large, and frequent, injections of exogenous proteins which have only short half lives in tissue.

Dwg. 0/5

Title Terms: INCORPORATE; THERAPEUTIC; GENE; VECTOR; BODY; CELL; IN-VIVO; VITRO; SUBSEQUENT; EXPRESS; SECRETION; ACTIVE; PROTEIN; TREAT; DEGENERATE ; DISEASE; SPINE; NERVE

Derwent Class: B04; D16

International Patent Class (Main): C12N-015/79

International Patent Class (Additional): A61K-048/00; C07K-015/00

File Segment: CPI